Wave Life Sciences logo
Wave Life Sciences
WVE | NASDAQ
Chart Builder DCF Calculator
$2.87
-$0.26 (-8.31%)
At close: Nov 16, 2026, 4:00 PM ET
$2.87
$0.00 (0.00%)
After-hours: Nov 16, 2026, 7:31 PM ET

Wave Life Sciences Company Profile

Company profile explained

Company Profile

Wave Life Sciences Ltd., a clinical-stage biotechnology company, designs, develops, and commercializes ribonucleic acid (RNA) medicines through PRISM, a discovery and drug development platform. The company’s medicines platform, PRISM combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. It is developing WVE-006, a GalNAc-conjugated RNA editing oligonucleotide for the treatment of alpha-1 antitrypsin deficiency; WVE-007, a GalNAc-conjugated small interfering RNA designed to silence INHBE mRNA targeting obesity; WVE-008, a GalNAc-conjugated RNA editing oligonucleotide for the treatment of liver disease; WVE-N531, an exon splicing oligonucleotide for the treatment of Duchenne muscular dystrophy; and WVE-003, an allele-selective oligonucleotide for the treatment of Huntington’s disease (HD). The company has collaboration agreements with GlaxoSmithKline for the research, development, and commercialization of oligonucleotide therapeutics; Takeda Pharmaceutical Company Limited for the research, development, and commercialization of oligonucleotide therapeutics for disorders of the Central Nervous System; and Asuragen, Inc. for the development and potential commercialization of companion diagnostics for investigational allele-selective therapeutic programs targeting HD. Wave Life Sciences Ltd. was founded in 2012 and is based in Singapore.

Key Executives

Name Position
Paul Bolno President, Chief Executive Officer & Director
Chandra Vargeese Chief Technology Officer
Kyle Moran Chief Financial Officer & Principal Accounting Officer
Christopher Francis Senior Vice President of Corporate Development & Head of Emerging Areas
Daryn Lewis Senior Vice President & Head of Human Resources
Erik Ingelsson Chief Scientific Officer
Gregory L. Verdine Founder & Director
Hsiu-Chiung Yang Senior Vice President of Translational Medicine
Kate Rausch Vic President of Corporate Affairs & Investor Relations
Katie Sullivan Senior Director of Corporate Communications
Linda Rockett Senior Vice President & General Counsel
Sridhar Vaddeboina Senior Vice President of Chemistry, Manufacturing & Controls

Latest SEC Filings

Date Type Title
Oct 27, 2026 SC 13G Statement of acquisition of beneficial ownership b...
Oct 27, 2026 SC 13G/A [Amend] Statement of acquisition of beneficial own...
Oct 27, 2026 10-Q Quarterly Report
Oct 27, 2026 8-K Current Report
Oct 14, 2026 ARS Filing
Oct 14, 2026 DEF 14A Filing
Oct 07, 2026 4 Filing
Oct 07, 2026 4 Filing
Oct 07, 2026 4 Filing
Oct 07, 2026 4 Filing
View All SEC Filings ➞
Wave Life Sciences
Wave Life Sciences logo
Country United States
IPO Date Nov 11, 2015
Industry Biotechnology
Sector Healthcare
Employees 317
CEO Paul Bolno

Contact Details

733 Concord Avenue Cambridge, Massachusetts 02138 United States

Stock Details

Ticker Symbol WVE
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001631574
CUSIP Number 94352A104
ISIN Number US94352A1043
SIC Code 2834

© 2026 bestshares.com. All rights reserved.

All data is for informational purposes only. bestshares.com is not a broker, dealer, or registered investment adviser, and nothing on this site is a recommendation to buy or sell any security.